• In late June 2026, Insmed Incorporated was removed from the NASDAQ-100 and multiple Russell indices, while also appointing industry veteran Samuele Butera as Senior Vice President, Global Respiratory, to lead its respiratory therapeutic area.
• This combination of index removals and a high-profile commercial hire highlights a pivotal moment for Insmed’s visibility, investor base, and future respiratory portfolio execution.
• We’ll now examine how Insmed’s removal from major indices shapes its existing investment narrative around brensocatib launches and respiratory growth.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Insmed Investment Narrative Recap

To own Insmed today, you need to believe brensocatib (BRINSUPRI) can scale commercially in bronchiectasis while ARIKAYCE and TPIP add meaningful follow‑on contributions. The near term focus remains the U.S. brensocatib launch and ongoing FDA review; index removals from the NASDAQ‑100 and Russell suites do not directly change that catalyst, but they can affect trading liquidity and short term sentiment, which may amplify volatility around regulatory or launch updates.

Against that backdrop, the appointment of Samuele Butera as Senior Vice President, Global Respiratory stands out. His track record launching complex respiratory and specialty drugs at Johnson & Johnson and Novartis aligns closely with Insmed’s need to execute on brensocatib, ARIKAYCE label expansion and future TPIP launches, at a time when the company is investing heavily in commercialization to support its respiratory growth story.

Yet, despite this progress, investors should also be aware that tighter payer policies or slower bron­chiectasis diagnosis trends could still...

Insmed's narrative projects $4.1 billion revenue and $1.0 billion earnings by 2029.

Uncover how Insmed's forecasts yield a $197.14 fair value, a 88% upside to its current price.

Exploring Other Perspectives

While consensus once assumed revenue could reach about US$3.6 billion and earnings US$159.6 million by 2029, the lowest analysts highlight how cautious physician uptake and index removals might justify a far more conservative view, so you should weigh these different expectations before deciding which version of Insmed’s future you find more convincing.

Explore 4 other fair value estimates on Insmed - why the stock might be a potential multi-bagger!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Insmed research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Insmed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insmed's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.